Novel therapeutic strategies for androgen-independent prostate cancer: An update
- 1 April 2004
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 31, 26-32
- https://doi.org/10.1053/j.seminoncol.2004.02.008
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Prostate-Specific Antigen-Activated Thapsigargin Prodrug as Targeted Therapy for Prostate CancerJNCI Journal of the National Cancer Institute, 2003
- Phase III Study of Mitoxantrone Plus Low Dose Prednisone Versus Low Dose Prednisone Alone in Patients With Asymptomatic Hormone Refractory Prostate CancerJournal of Urology, 2002
- PACLITAXEL AND DOCETAXEL IN PROSTATE CANCERHematology/Oncology Clinics of North America, 2001
- NONANDROGENIC MEDIATORS OF PROSTATIC GROWTHHematology/Oncology Clinics of North America, 2001
- Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyJournal of Clinical Oncology, 1999
- p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapyUrology, 1998
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.Journal of Clinical Oncology, 1996
- Antagonistic effect of androgen on prostatic cell deathThe Prostate, 1984
- The veterans administration cooperative urological research group's studies of cancer of the prostateCancer, 1973
- THE RESULTS OF DOUBLE CASTRATION IN HYPERTROPHY OF THE PROSTATEAnnals of Surgery, 1895